Background Investigation Methods, Corporate Intelligence & Due Diligence, e-Discovery Techniques, Investigation & Intelligence Feeds, Judgment Enforcement, Legal Enforcement Cases, Legal Ethics & Intelligence, Legal Technology & Intelligence, Witness Credibility Analysis

Teva and Prestige Biopharma Enter Licensing Agreement to Commercialize Their Trastuzumab Biosimilar

Posted by author-avatar
0
Test Logo Transparent

On October 20, 2025, Teva Pharmaceuticals International GmbH (“Teva”) announced a licensing agreement with Prestige BioPharma Ltd. (“Prestige BioPharma”) to commercialize TUZNUE® (trastuzumab), a biosimilar to Genentech’s HERCEPTIN (trastuzumab), in a majority of European countries….
By: Goodwin

Newer
FDA Approves Genentech’s GAZYVA® (obinutuzumab)
Back to list
Older AI That Works In The Real World: Lessons From A Legal Ops Playbook

Leave a Reply

Your email address will not be published. Required fields are marked *